Publication

Impact of single-nucleotide polymorphisms in DNA repair pathway genes on response to chemoradiotherapy in rectal cancer patients: Results from ACCORD-12/PRODIGE-2 phase III trial

ANNÉE

2019

AUTEURS

Boige V, Mollevi C, Gourgou S, Azria D, Seitz JF, Vincent M, Bigot L, Juzyna B, Miran I, Gerard JP, Laurent-Puig P

CONGRÈS/REVUE

Int J Cancer

LIEN PUBLICATIONS ASSOCIÉES

https://doi.org/10.1002/ijc.32417

Adjuvant chemotherapy versus perioperative chemotherapy (CTx) for resectable gastric signet ring cell (SRC) gastric cancer: A multicenter, randomized phase II study (PRODIGE 19)

ANNÉE

2019

AUTEURS

Eveno C, Adenis A, Bouche O, Le Malicot K, Hautefeuille V, Faroux R, Bidault A, Egreteau J, Meunier B, Mabro M, Carrère N, Barriere N, Ben Abdelghani M, Mauvais F, Fiore F, Malka D, Manfredi S, Piessen G

CONGRÈS/REVUE

ASCO

LIEN PUBLICATIONS ASSOCIÉES

https://meetings.asco.org/abstracts-presentations/173271

Continuation of Bevacizumab vs Cetuximab Plus Chemotherapy After First Progression in KRAS Wild-Type Metastatic Colorectal Cancer: The UNICANCER PRODIGE18 Randomized Clinical Trial

ANNÉE

2019

AUTEURS

Bennouna J, Hiret S, Bertaut A, Bouche O, Deplanque G, Borel C, Francois E, Conroy T, Ghiringhelli F, des Guetz G, Seitz JF, Artru P, Hebbar M, Stanbury T, Denis MG, Adenis A, Borg C

CONGRÈS/REVUE

JAMA Oncol

LIEN PUBLICATIONS ASSOCIÉES

https://doi.org/10.1001/jamaoncol.2018.4465

FOLFOX alone or combined with rilotumumab or panitumumab as first-line treatment for patients with advanced gastroesophageal adenocarcinoma (PRODIGE 17-ACCORD 20-MEGA): a randomised, open-label, three-arm phase II trial

ANNÉE

2019

AUTEURS

Malka D, François E, Penault-Llorca F, Castan F, Bouché O, Bennouna J, Ghiringhelli F, de la Fouchardière C, Borg C, Samalin E, Bachet JB, Raoul JL, Miglianico L, Bengrine-Lefèvre L, Dahan L, Lecaille C, Aparicio T, Stanbury T, Perrier H, Cayre A, Laurent-Puig P, Gourgou S, Emile JF, Taïeb J

CONGRÈS/REVUE

Eur J Cancer

LIEN PUBLICATIONS ASSOCIÉES

https://doi.org/10.1016/j.ejca.2019.04.020

Circulating Tumor Cells and Circulating Tumor DNA Detection in Potentially Resectable Metastatic Colorectal Cancer: A Prospective Ancillary Study to the Unicancer Prodige-14 Trial

ANNÉE

2019

AUTEURS

Bidard FC, Kiavue N, Ychou M, Cabel L, Stern MH, Madic J, Saliou A, Rampanou A, Decraene C, Bouche O, Rivoire M, Ghiringhelli F, Francois E, Guimbaud R, Mineur L, Khemissa-Akouz F, Mazard T, Moussata D, Proudhon C, Pierga JY, Stanbury T, Thezenas S, Mariani P

CONGRÈS/REVUE

Cells

LIEN PUBLICATIONS ASSOCIÉES

https://doi.org/10.3390/cells8060516

Gemcitabine and Oxaliplatin Chemotherapy or Surveillance in Resected Biliary Tract Cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): A Randomized Phase III Study

ANNÉE

2019

AUTEURS

Edeline J, Benabdelghani M, Bertaut A, Watelet J, Hammel P, Joly JP, Boudjema K, Fartoux L, Bouhier-Leporrier K, Jouve JL, Faroux R, Guerin-Meyer V, Kurtz JE, Assénat E, Seitz JF, Baumgaertner I, Tougeron D, de la Fouchardière C, Lombard-Bohas C, Boucher E, Stanbury T, Louvet C, Malka D, Phelip JM

CONGRÈS/REVUE

J Clin Oncol

LIEN PUBLICATIONS ASSOCIÉES

https://doi.org/10.1200/jco.18.00050

Impact of single-nucleotide polymorphisms in DNA repair pathway genes on response to chemoradiotherapy in rectal cancer patients: Results from ACCORD-12/PRODIGE-2 phase III trial

ANNÉE

2019

AUTEURS

Boige V, Mollevi C, Gourgou S, Azria D, Seitz JF, Vincent M, Bigot L, Juzyna B, Miran I, Gerard JP, Laurent-Puig P

CONGRÈS/REVUE

Int J Cancer

LIEN PUBLICATIONS ASSOCIÉES

https://doi.org/10.1002/ijc.32417

Pravastatin combination with Sorafenib does not improve survival in advanced Hepatocellular Carcinoma

ANNÉE

2019

AUTEURS

Jouve JL, Lecomte T, Bouche O, Barbier E, Akouz FK, Riachi G, Khac EN, OllivierHourmand I, Debette-Gratien M, Faroux R, Villing AL, Vergniol J, Ramee JF, Bronowicki JP, Seitz JF, Legoux JL, Denis J, Manfredi S, Phelip JM

CONGRÈS/REVUE

J Hepatol

LIEN PUBLICATIONS ASSOCIÉES

https://doi.org/10.1016/j.jhep.2019.04.021

Sorafenib alone vs sorafenib plus GEMOX as 1st-line treatment for advanced HCC: the phase II randomised PRODIGE 10 trial

ANNÉE

2019

AUTEURS

Assenat E, Pageaux GP, Thézenas S, Peron JM, Bécouarn Y, Seitz JF, Merle P, Blanc JF, Bouché O, Ramdani M, Poujol S, de Forges H, Ychou M, Boige V

CONGRÈS/REVUE

Br J Cancer

LIEN PUBLICATIONS ASSOCIÉES

https://doi.org/10.1038/s41416-019-0443-4

Clinical outcome between familial and sporadic origin for MSI colon cancer patients treated with adjuvant FOLFOX +/- cetuximab: A pooled analysis of the PETACC8 and NCCTG N0147 (Alliance) trials

ANNÉE

2019

AUTEURS

Zaanan A, Shi Q, Taieb J, Alberts S, Meyers J, Smyrk T, Julié C, Zawadi A, Tabernero J, Mini E, Goldberg R, Folprecht G, Laethem J, Le Malicot K, Sargent D, Laurent-Puig P, Sinicrope FA

CONGRÈS/REVUE

JCO Precision Oncology

LIEN PUBLICATIONS ASSOCIÉES

https://ascopubs.org/doi/abs/10.1200/PO.19.00237